InvestorsHub Logo
Followers 335
Posts 19013
Boards Moderated 0
Alias Born 08/25/2007

Re: None

Wednesday, 09/13/2017 11:03:28 AM

Wednesday, September 13, 2017 11:03:28 AM

Post# of 8299
The Company is reviewing clinical, regulatory and financial options with regard to the levosimendan program
The Company’s Board of Directors is continuing its review of strategic alternatives with the assistance of their financial advisors at Ladenburg Thalmann & Co. Inc. Strategic alternatives

http://investors.tenaxthera.com/prviewer/release_only/id/2617608

DONT LISTEN TO ME IM CANADIANNNNNNNN

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TENX News